The discovery of the latest markers helps non-invasive diagnosis of liver cancer patients

Share This Post

A medical technology company focused on developing innovative technologies for early diagnosis of cancer, today announced new research results. A clinical study of liver cancer has demonstrated the great potential of LAM’s new DNA methylation-based biomarker to detect hepatocellular carcinoma (HCC) The detection sensitivity is 95% and the specificity is 97.5%.

In this study, stock samples of 130 subjects were collected, including: 60 subjects diagnosed with hepatocellular carcinoma (stage I to IV), 30 subjects without liver disease, 10 Subjects diagnosed with benign liver disease and 30 subjects diagnosed with breast cancer, colorectal cancer or lung cancer. DNA was extracted from the sample, the DNA was transformed with bisulfite, and DNA methylation was quantified using the IvyGene platform. After completing the data collection and analysis of all samples, blind the samples to calculate the test performance.

A total of 57 of the 60 samples taken from patients with hepatocellular carcinoma were correctly identified, with an overall calculated sensitivity of 95%. The sensitivity difference between detecting stage I and stage IV hepatocellular carcinoma was small (range 89% to 100%). Of the samples taken from cancer patients other than liver cancer, 90% of breast cancer samples, 80% of colorectal cancer samples, and 90% of lung cancer samples were correctly identified as non-liver cancer, and the total calculated specificity was 87%.

For details on best options for liver cancer treatment, do call us at +91 96 1588 1588 or write to

Subscribe To Our Newsletter

Get updates and never miss a blog from Cancerfax

More To Explore

Seattle Children's Hospital to Start CAR T-Cell Clinical Trial for Pediatric Lupus Patients
CAR T-Cell therapy

Seattle Children’s Hospital to Start CAR T-Cell Clinical Trial for Pediatric Lupus Patients

Seattle Children’s Hospital is launching a groundbreaking CAR T-cell clinical trial for pediatric lupus patients. This innovative approach harnesses the body’s immune cells to target and eliminate lupus-affected cells, offering new hope for young patients with this autoimmune disorder. The trial represents a significant advancement in lupus treatment, aiming to improve outcomes and reduce long-term complications for children suffering from this challenging condition.

Efficacy of CAR T Cell Therapy in B-Cell lymphoma Richter Transformation
CAR T-Cell therapy

Efficacy of CAR T Cell Therapy in B-Cell lymphoma Richter Transformation

CAR T cell therapy has shown promising efficacy in treating B-cell lymphoma Richter Transformation, a rare and aggressive disease. This advanced therapy involves genetically modifying a patient’s T cells to target and destroy cancerous B cells. Clinical trials indicate significant response rates, with some patients achieving complete remission. Despite challenges like potential severe side effects, CAR T cell therapy represents a groundbreaking approach, offering hope for improved outcomes in this difficult-to-treat condition.

Need help? Our team is ready to assist you.

We wish a speedy recovery of your dear and near one.

Start chat
We Are Online! Chat With Us!
Scan the code

Welcome to CancerFax !

CancerFax is a pioneering platform dedicated to connecting individuals facing advanced-stage cancer with groundbreaking cell therapies like CAR T-Cell therapy, TIL therapy, and clinical trials worldwide.

Let us know what we can do for you.

1) Cancer treatment abroad?
2) CAR T-Cell therapy
3) Cancer vaccine
4) Online video consultation
5) Proton therapy